Janssen Biotech submits NDA to FDA for apalutamide to treat non-metastatic CRPC

Janssen Biotech has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for apalutamide to treat male patients with non-metastatic castration-resistant prostate cancer (CRPC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news